Presentation, Management, and Outcomes of Patients with Giant Pheochromocytoma: Retrospective Cohort Study

Bahar Bahrani Fard; Nasrin Nikravangolsefid; Justin W Maroun; Ashton Cross; Trenton Foster; Travis J McKenzie; Benzon Dy; Melanie Lyden; William F Young Jr; Irina Bancos

doi:10.1210/clinem/dgae612

Presentation, Management, and Outcomes of Patients with Giant Pheochromocytoma: Retrospective Cohort Study

J Clin Endocrinol Metab. 2024 Sep 4:dgae612. doi: 10.1210/clinem/dgae612. Online ahead of print.

Authors

Affiliations

¹ Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, 55905, USA.
² Division of Nephrology and Hypertension, Mayo Clinic Rochester, MN, 55905, USA.
³ Department of Surgery, Mayo Clinic Rochester, MN, 55905, USA.
⁴ Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, MN, 55905, USA.

PMID: 39230590
DOI: 10.1210/clinem/dgae612

Abstract

Context: Data on giant pheochromocytomas (PHEO), defined based on size ≥ 10 cm, are scarce.

Objective: to compare presentation, management, and outcomes of patients with giant vs non-giant PHEOs.

Design: retrospective cohort study, 2000-2023.

Setting: referral center.

Patients: consecutive patients with giant PHEO and randomly chosen patients with non-giant PHEO (referents) at a 1:6 ratio.

Outcomes: perioperative complications, metastases, mortality.

Results: Of 828 patients with PHEO, 31 (3.7%) had giant PHEO (median size 12 cm, IQR 10.0-13.5). In comparison to referents (n=186, median size 4 cm, IQR, 2.9-5.0), patients with giant PHEO had more symptoms of catecholamine excess (median of 2 vs 1, P=.04) and presented with a higher prevalence of severe catecholamine excess (76% vs 30%, P<.0001).Adrenalectomy was performed in 94% of patients with giant PHEOs and 100% referents. In addition to preoperative alpha-adrenergic blockade (89%), metyrosine was used in 14 (7%) patients, mostly in patients with giant PHEO (26% vs 3%, P<.0001). Patients with giant PHEO had a higher perioperative complication rate (31% vs 10%, P=.004).During a median follow-up of 3 years, metastases developed at a higher rate in patients with giant PHEOs (45% vs 4% in referents, P<.0001). Disease-specific mortality was 7% in patients with giant PHEOs and 0% in referents (P=.02).

Conclusion: Patients with giant PHEO as compared to referents were more symptomatic, had a higher degree of catecholamine excess, and had a higher rate of perioperative complications. Almost half of patients with giant PHEO developed metastases, warranting a close follow-up.

Keywords: adrenal mass; adrenalectomy; diagnosis; metastases; outcomes; size.

© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.